Oryzon Genomics, and Functional Neuromodulation, and participated in scientific advisory boards of Functional Neuromodulation ,
, HH is a co-inventor in the following patents as a scientific expert and has received no royalties: ? In Vitro Multi-parameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Patent Number, p.8916388
, ? In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Patent Number, p.8298784
, ? Neurodegenerative Markers for Psychiatric Conditions Publication Number
, ? In Vitro Multi-parameter Determination Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number
, ? In Vitro Method for The Diagnosis and Early Diagnosis of Neurodegenerative Disorders Publication Number
, ? In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases Publication Number
, ? In Vitro Method for The Diagnosis of Neurodegenerative Diseases Patent Number, p.7547553
, ? CSF Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases Publication Number
, ? In Vitro Method for The Diagnosis of Neurodegenerative Diseases Publication Number
, ? Neurodegenerative Markers for Psychiatric Conditions Publication Number
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study, Alzheimers Dement, vol.11, issue.8, pp.964-74, 2015. ,
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum, Brain, vol.138, pp.1370-81, 2015. ,
Post-mortem histopathology underlying beta-amyloid PET imaging following flutemetamol F 18 injection, Acta neuropathol commun, vol.4, issue.1, p.130, 2016. ,
Brain PET in the diagnosis of Alzheimer's disease, Clin Nuclear Med, vol.39, issue.10, pp.413-435, 2014. ,
Phases of A beta-deposition in the human brain and its relevance for the development of AD, Neurology, vol.58, issue.12, pp.1791-800, 2002. ,
In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum, Ann Neurol, vol.80, issue.2, pp.247-58, 2016. ,
In vivo staging of regional amyloid deposition, Neurology, vol.89, issue.20, pp.2031-2039, 2017. ,
Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis, Acta Psychiatr Scand, vol.130, issue.6, pp.439-51, 2014. ,
Alzheimer's disease: definition, natural history, and diagnostic criteria, Alzheimers Dement, vol.12, issue.3, pp.292-323, 2016. ,
Memory complaints and risk of cognitive impairment after nearly 2 decades among older women, Neurology, vol.85, issue.21, pp.1852-1860, 2015. ,
Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study, Lancet Neurol, vol.17, issue.4, pp.335-381, 2018. ,
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-? plaques: a prospective cohort study, Lancet Neurol, vol.11, issue.8, pp.669-78, 2012. ,
Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects, J Nucl Med, vol.53, issue.3, pp.378-84, 2012. ,
Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, vol.12, issue.3, pp.189-98, 1975. ,
Cued and uncued memory tests: norms in elderly adults from the 3 cities epidemiological study, Rev Neurol, vol.163, issue.2, pp.205-226, 2007. ,
Cued recall in amnesia, J Clin Neuropsychol, vol.6, issue.4, pp.433-473, 1984. ,
Memory binding test distinguishes amnestic mild cognitive impairment and dementia from cognitively normal elderly, Arch Clin Neuropsychol, vol.32, issue.1, pp.29-39, 2017. ,
Differential behavioral effects in frontal lobe disease, Neuropsychologia, vol.6, issue.1, pp.53-60, 1968. ,
Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level, Acta Neurol Belg, vol.90, issue.4, pp.207-224, 1990. ,
What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults, Front Psychol, vol.5, p.772, 2014. ,
Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test, Clin Neuropsychol, vol.13, issue.1, pp.30-47, 1999. ,
WMS-III Wechsler memory scale-third edition, 1997. ,
The backward span of the Corsi Block-Tapping Task and its association with the WAIS-III Digit Span, Assessment, vol.15, issue.4, pp.426-460, 2008. ,
Trail Making Test A and B: normative data stratified by age and education, Arch Clin Neuropsychol, vol.19, issue.2, pp.203-217, 2004. ,
The FAB: a Frontal Assessment Battery at bedside, Neurology, vol.55, issue.11, pp.1621-1627, 2000. ,
Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds, Ann Nucl Med, vol.32, issue.2, pp.75-86, 2018. ,
Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects, J Cereb Blood Flow Metab, vol.12, issue.4, pp.571-83, 1992. ,
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest, NeuroImage, vol.31, issue.3, pp.968-80, 2006. ,
PETPVE12: an SPM toolbox for partial volume effects correction in brain PET-application to amyloid imaging with AV45-PET, NeuroImage, vol.147, p.8, 2017. ,
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET, Alzheimers Dement, vol.11, issue.1, pp.1-15, 2015. ,
Cerebellar amyloid-beta plaques: how frequent are they, and do they influence 18F-Florbetaben SUV ratios?, J Nucl Med, vol.57, issue.11, pp.1740-1745, 2016. ,
Amyloid-? imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods, J Nuclear Med, vol.54, issue.1, pp.70-77, 2013. ,
Use of florbetapir-PET for imaging beta-amyloid pathology, JAMA, vol.305, issue.3, pp.275-83, 2011. ,
Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease, Arch Neurol, vol.68, issue.11, pp.1404-1415, 2011. ,
18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-? pathology, Alzheimers Dement, vol.11, issue.8, pp.975-85, 2015. ,
Performance of [(18)F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. Alzheimer's Dementia, vol.9, pp.25-34, 2017. ,
Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation, Brain, vol.138, pp.2020-2053, 2015. ,
DOI : 10.1093/brain/awv112
URL : https://academic.oup.com/brain/article-pdf/138/7/2020/13799993/awv112.pdf
Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease, Geriatr Gerontol Int, vol.15, issue.8, pp.961-969, 2015. ,
Memory binding test predicts incident amnestic mild cognitive impairment, J Alzheimers Dis, vol.53, issue.4, pp.1585-95, 2016. ,
DOI : 10.3233/jad-160291
Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5, Alzheimers Dementia, vol.3, issue.4, pp.668-77, 2017. ,
Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review, Alzheimers Res Ther, vol.5, issue.6, p.58, 2013. ,
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease, Neurobiol Aging, vol.56, pp.25-32, 2017. ,
DOI : 10.1016/j.neurobiolaging.2017.04.004
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505233
Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons, JAMA, vol.317, issue.22, pp.2305-2321, 2017. ,
DOI : 10.1001/jama.2017.6669
URL : https://jamanetwork.com/journals/jama/articlepdf/2631529/jama_donohue_2017_oi_170051.pdf
Detectable neuropsychological differences in early preclinical Alzheimer's disease: a meta-analysis, Neuropsychol Rev, vol.27, issue.4, pp.305-330, 2017. ,
Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample, Alzheimers Dementia, vol.10, issue.6, pp.735-777, 2014. ,
Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease, J Int Neuropsychol Soc, vol.14, issue.2, pp.266-78, 2008. ,
Establishing composite cognitive endpoints for use in preclinical Alzheimer's disease trials, J Prev Alzheimer's Dis, vol.2, issue.1, pp.2-3, 2015. ,
Subjective cognitive complaints and amyloid burden in cognitively normal older individuals, Neuropsychologia, vol.50, issue.12, pp.2880-2886, 2012. ,
DOI : 10.1016/j.neuropsychologia.2012.08.011
URL : http://europepmc.org/articles/pmc3473106?pdf=render
Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol, vol.82, issue.4, pp.239-59, 1991. ,
Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance, J Neurol Neurosurg Psychiatry, vol.89, issue.4, pp.410-417, 2018. ,
Prevalence and severity of cerebral amyloid angiopathy: a populationbased study on very elderly Finns (Vantaa 85+), Neuropathol Appl Neurobiol, vol.38, issue.4, pp.329-365, 2012. ,
Resistance vs resilience to Alzheimer disease, Clarifying Terminol Preclin Stud, vol.90, issue.15, pp.695-703, 2018. ,
DOI : 10.1212/wnl.0000000000005303
Youthful memory capacity in old brains: anatomic and genetic clues from the Northwestern SuperAging Project, J Cogn Neurosci, vol.25, issue.1, pp.29-36, 2013. ,
Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons, JAMA, vol.317, issue.22, pp.2305-2321, 2017. ,
DOI : 10.1001/jama.2017.6669
URL : https://jamanetwork.com/journals/jama/articlepdf/2631529/jama_donohue_2017_oi_170051.pdf
The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's Dementia, vol.11, pp.757-71, 2015. ,
DOI : 10.1016/j.jalz.2015.05.001
URL : http://europepmc.org/articles/pmc4510459?pdf=render
, Amyloid burden in healthy aging: regional distribution and cognitive consequences, vol.78, pp.387-95, 2012.
Indicators of amyloid burden in a population-based study of cognitively normal elderly, Neurology, vol.79, issue.15, pp.1570-1577, 2012. ,
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements, J Nucl Med, vol.50, issue.3, pp.348-55, 2009. ,
Quantification of [18F]florbetapir: a test-retest tracer kinetic modelling study, J Cereb Blood Flow Metab, 2018. ,
Validation of the semiquantitative static SUVR method for (18)F-AV45 PET by pharmacokinetic modeling with an arterial input function, J Nucl Med, vol.58, issue.9, pp.1483-1492, 2017. ,
The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease, Eur J Nucl Med Mol Imaging, vol.38, issue.6, pp.1104-1123, 2011. ,
Partial volume correction in quantitative amyloid imaging, NeuroImage, vol.107, pp.55-64, 2015. ,
Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction, NeuroImage, vol.108, pp.450-459, 2015. ,
Impact of spillover from white matter by partial volume effect on quantification of amyloid deposition with, PiB PET. NeuroImage, vol.143, issue.11, pp.316-340, 2016. ,
Alzheimer's disease neuroimaging I. PETPVE12: an SPM toolbox for partial volume effects correction in brain PET-application to amyloid imaging with AV45PET, NeuroImage, vol.147, pp.669-77, 2017. ,
Partial-volume effect correction improves quantitative analysis of 18FFlorbetaben beta-amyloid PET scans, J Nucl Med, vol.57, issue.2, pp.198-203, 2016. ,